{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

US4001270_TOT - United States Patent[19[1 1 4,001,270...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Background image of page 2
Background image of page 3
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: United States Patent [19] [1 1] 4,001,270 Alexander et al. [45] Jan. 4, 1977 [54] 9-BENZOYL-I,2,3,4-TETRAHYDROCAR- [51] Int. Cl.2 ...................................... C07D 209/86 BAZOLE [58] Field of Search .................................... 260/315 [75] Inventors: Ernest John Alexander, East . Greenbush; Aram Mooradian, [56] References and Schodack, both of NY. UNITED STATES PATENTS [73] Assignee: Sterling Drug Inc., New York, NY. 3,868,387 2/1975 Berger et a1. ...................... 260/315 [22] filed: Dec. 12’ 1975 Primary Exaininer-Henry R. Jiles [21] APPL NOJ 640,249 Assistant Examiner—R. W. Ramsuer Attorney, Agent, or Firm—Frederik W. Stonner; B. Related US. Application Data Woodrow Wyatt ' [63] Continuation-impart ot‘ Ser. No. 514,767, Oct. 15, I974, Pat. No. 3,948,939, which is a [57] ABSTRACT continuation-in-part of Ser. No. 314,099, Dec. 11, 9-Benzoyl-3-hydroxymethyl-l,2,3,4-tetrahydrocar— 1972.’ Pat: NC?‘ 3’905’998’ Wh'Ch ‘5 a bazole and 9-benzoy1-3-(N—phenylcarbamoyloxyme- contmuation-m-part of Ser. No. 200,205, Nov. 18, - - 1971 P . . thyl)-1,2,3,4-tetrahydrocarbazole, havmg respectively , at. No. 3,758,496, which IS a .. . . . . . . continuation-in-part of Ser. No. 42 620 June 2 1970 antimflammatory and antibacterial activmes, and their Pat. No. 3,687,969. ' ' ’ ’ preparation are described. [52] US. Cl. ............................ 260/315; 260/340.9; 424/274 1 Claim, No Drawings 4,001,270 1 9—BENZOYL-1,2,3,4-TETRAHYDROCARBAZOLE CROSS-REFERENCES TO RELATED APPLICATIONS This application is a continuation~in-part of copend— ing application Ser. No. 514,767, filed Oct. 15, 1974, now US. Pat. No. 3,948,939, issued Apr. 6, 1976, in turn a continuation-in-part of application Ser. No. 314,099, filed Dec. 11, 1972, now US. Pat. No. 3,905,998, issued Sept. 16, 1975, in turn a continua— tion—in-part of Ser. No. 200,205, filed Nov. 18, 1971, now U.S. Pat. No. 3,758,496, issued Sept. 11, 1973, in turn a continuation—in—part of Ser. No. 42,620, filed June 2, 1970, now US. Pat. No. 3,687,969, issued Aug. 29, 1972. BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to 9ubenzoyl-3-(CH20Y)- 1 ,2,3 ,4-tetrahydrocarbazoles. 2. Description of the Prior Art 9-Benzoy1-1,2,3,4,—tetrahydrocarbazoles, having an— tiphlogistic, analgesic, antifebric and sedative proper- ties, are described in British Patent Specification No. 1,183,093, published Mar. 4, 1970. 4—Hydroxymethyl— 9-methy1—1,2,3,4—tetrahydrocarbazole, an intermediate for corresponding 4-aminomethyl compounds, is de- scribed in US. Pat. No. 3,752,823, issued Aug. 14, 1973. SUMMARY OF THE INVENTION The invention provides a composition of matter de- fined as a 9-benzoyl-3-(CH20Y)-1,2,3,4-tetrahy- drocarbazole of the formula CH20Y CI , l. N I C =0 wherein Y is hydrogen or N—phenylcarbamoyl. ' The compound of the invention having formula 1 wherein Y is hydrogen was found to be useful as an antiinflammatory agent when tested in pharmacologi- cal test procedures described hereinbelow. The compound of the invention having formula I wherein Y is N-phenylcarbamoyl was found to be use- ful as an antibacterial agent when tested as described hereinbelow. DETAILED DESCRIPTION OF THE INVENTION The molecular structures of the compounds of the invention were assigned on the basis of the method of their synthesis and study of their infrared Spectra, and confirmed by the correspondence between calculated and found values for the elementary analysis. The compounds of the invention were prepared as follows: 10 15 20 25 30 35 4O 45 50 55 60 65 2 EXAMPLE 1 9-Benzoy1-3-hydroxymethyl— l ,2,3,4-tetrahydrocar- bazole (formula 1, Y=hydrogen) l-Benzoyl- 1 -pheny1hydrazine hydrochloride (23.8 g.) and 18 g. of 4—hydroxymethylcyclohexanone ethyl- ene ketal in 450 ml. of absolute ethyl alcohol was heated under reflux for four hours. The chilled mixture was filtered, the filtrate was evaporated to dryness under reduced pressure and the resulting residue was dissolved in ether. The ether solution was washed with water, dilute hydrochloric acid. water, dilute sodium bicarbonate, and water, dried and evaporated to dry- ness to give, after recrystallization from ethyl acetate— hexane, 9.6 g. of 9—benzoyl—34hydroxymethyl-l,2,3,4- tetrahydrocarbazole; m.p. 105°—1()7° C. Preparation of 4-Hydroxymethylcyclohexanone ethylene ketal Ethyl cyclohexanone-4-carboxylate (335 g.), 550 ml. ethylene glycol and 21 g. of p-toluenesulfonic acid in 5.5 liters of benzene were heated at reflux with stirring for 24 hours while water was separated by means of a water trap. The mixture was cooled and poured into 4 liters of ice water. The benzene layer was separated. washed with 1 liter of 5% sodium bicarbonate, 1 liter of water and 1 liter of saturated sodium chloride solution. dried and evaporated to dryness to give, after distilla- tion, 245.6 g. of ethyl cyclohexanone-4-carboxylate ethylene ketal; b.p. 95°—99.5° C. (0.07 mm.); n25 D 1.4620. A solution of 35 g. of the ketal~ester in 50 ml. of dry tetrahydrofuran was added dropwise to 5.7 g. of lithium aluminum hydride in 250 ml. of dry tetrahydro- furan, and the mixture was heated at reflux for five hours and cooled to room temperature. A saturated sodium chloride solution (11.4 ml.) was added drop— wise and heating at reflux was continued for one hour. The mixture was cooled and filtered, and the filtrate was dried and evaporated to dryness to give 26.9 g. of 4—hydroxymethylcyclohexanone ethylene ketal as a clear, colorless oil which was used without further puri- fication. EXAMPLE 2 9-Benzoyl-3-( N-phenylcarbamoyloxymethyl)- 1 ,2,3,4— tetrahydrocarbazole (formula I, Y = N-phenylcarbamoyl) 9-Benzoyl—3-hydroxymethyl— 1 ,2 ,3 ,4—tetrahydrocar— bazole (9.8 g.) and phenylisocyanate (4.2 g.) were combined and heated on a steam bath for one and one-half hours. The mixture was cooled and triturated in ether and the resulting solid was collected by filtra- tion and washed with ether to give 7.1 g. of the title compound; m.p. 140°—143° C. The antiinflammatory activity of 9-benzoyl-3- hydroxymethyl— 1 ,2,3,4—tetrahydr0carbazole was deter- mined by its ability to inhibit in rats carrageenin- induced foot edema and adjuvant-induced arthritis. A brief description of the pharmacological test proce- dures employed follows. Inhibition of Carrageenin-Induced Foot Edema in Rats Young male rats weighing 100—1 10 g. are used. Food is withdrawn approximately 18 hours prior to medica- tion but the animals are permitted free access to drink- ing water up to the time of medication. Drugs to be tested are suspended by triturating in 1% gum traga- 4,001,270 3 canth using ground glass homogenizers and adminis- tered by gavage in a volume of l ml/100 g body weight. Control animals receive the gum tragacanth only. One hour after medication, 0.05 ml of 1% suspension of carrageenin in 0.9% saline is injected into the plantar tissue of the left hind paw. Three hours after injection of the carrageenin, edema formation, i.e., increase in foot volume (difference between left hind paw and the uninjected right hind paw) is measured plethysmo- graphically in the unanesthetized rat. inhibition Adjuvant—lnduced Arthritis in Rats Adult male rats weighing 200—230 grams are used. Adjuvant (M. butyricum), 0.1 ml of a 0.6% suspension in heavy mineral oil, is injected into the plantar tissue of the left hind paw. A negative control group is in- jected with mineral oil only. Beginning on the ninth day after adjuvant injection (polyarthritis does not appear until approximately the tenth day after ad juvant admin- istration), the animals receive 6 daily medications of test compound suspended by triturating in 1% gum tragacanth using a ground glass homogenizer and ad- ministered by gavage in a volume of 1 ml/100 g body weight. Both the negative control and adjuvant injected control animals receive the vehicle only. Food and 5 10 15 20 25 water are permitted ad libitum. Twenty-four hours ' after the last medication, the animals are weighed, the degree of arthritic involvement, i.e., increase in foot volume and plasma inflammation units are determined. Foot volume is measured plethysmographically in the unanesthetized rat. 30 35 40 45 50 55 60 65 4 9-Benzoy1-3-hydroxymethy1-1,2,3,4-tetrahydrocar- bazole was found to be active when tested in rats at 100 mg./kg. of body weight in the Inhibition of Carragee- nin-Induced Foot Edema and Adjuvant-lnduced Ar- thritis Test Procedures described above and is indi- cated for use as an antiinflammatory agent. This com- pound can be prepared for use by following conven~ tional pharmaceutical procedures; that is, it can be incorporated in unit dosage form in tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia, and the like; or as an aqueous or oil suspension or solution in a pharmaceutically acceptable vehicle such as aqueous alcohol, glycol, oil solution or oil water emulsion for oral or parenteral administration. 9-Benzoyl-3—( N-phenylcarbamoyloxymethyl )- 1,2,3,4-tetrahydrocarbazole, when tested in the Auto- titer method described by Goss et al., Applied Microbi— ology 16 (No. 9), 1414—1416(1968), was found to be antibacterially effective against Pseudomonas aerugin- am at a concentration of 125 meg/m1. thus indicating the utility of this compound as an antibacterial agent against Pseudomonas aeruginosa. This compound may be formulated for use by conventional procedures, e.g., for application to inanimate surfaces; it can be formu— lated as a dilute solution in an aqueous medium or in a solution containing a surfactant and is applied to the surface to be disinfected by conventional means such as spraying, swabbing, immersion and the like. We claim: 1 . 9-Benzoyl-3—( N~phenylcarbamoyloxymethyl )~ 1 ,2,3 .4—tetrahydrocarbazole. * >I= * =1t * ...
View Full Document

{[ snackBarMessage ]}

Page1 / 3

US4001270_TOT - United States Patent[19[1 1 4,001,270...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon bookmark
Ask a homework question - tutors are online